Clinical Trial

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

Study acronym: Cardinal COPD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.
Protocol Amendment History 1 change
notable Trial sites expanded: 14 -> 34 locations 2026-08-13
Trial Details
NCT Number NCT07610395
Lead Sponsor Altesa Biosciences, Inc.
Conditions Rhinovirus Infection
Enrollment 180 participants
Start Date 2026-05-01
Primary Completion 2027-11-15 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12